Bedside Pediatric Warning System Failed To Decrease Hospital Deaths: Study

Canadian researchers were disappointed to find that the addition of bedside early warning systems do not appear to lower death rates for hospitalized children. 

In fact, in a study published in the Journal of the American Medical Association (JAMA), mortality rates were slightly higher among child patients when hospitals installed Bedside Paediatric Early Warning Systems (BedsidePEWS) when compared to the usual care used to prevent serious death and injury.

BedsidePEWS is a documentation-based system of care, which the study describes as being “composed of a validated severity of illness score, an interprofessionally designed documentation record, and multidomain recommendations for care escalation and de-escalation among hospitalized patients from term to 18 years of age.” It tracks patient vital signs and combines that with routine clinical assessments, and then generates a score that tries to quantify the patient’s severity of illness.

Did You Know?

Ticketmaster Data Breach Impacts Millions of Customers

A massive Ticketmaster data breach exposed the names, addresses, phone numbers, credit card numbers and other personal information of more than 560 million customers, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

The system is supposed to give health care providers a leg up on unexpected health problems and guide them to take preventative actions long before problems occur.

The study consisted of a randomized clinical trial involving 21 hospitals, 144,539 patient discharges, and 559,443 patient days in Belgium, Canada, England, Ireland, New Zealand and the Netherlands from February 2011 through June 2015. The study looked at impatient pediatric care for children ranging from newborns to teenagers under the age of 18.

In 10 hospitals, doctors used BedsidePEWS systems, and 11 of the facilities used standard care. The study looked at rates of all-cause hospital mortality among children, as well as significant clinical deterioration events.

According to the findings, there were 1.56 deaths per 1,000 patient discharges at hospitals that provided regular care to its pediatric patients. That compares to 1.93 deaths per 1,000 patients at hospitals that used the early warning systems; an increase. There was a slight decrease in significant clinical deterioration events when BedsidePEWS were used, but the decrease was not large enough to be significant, researchers said.

“Implementation of the Bedside Paediatric Early Warning System compared with usual care did not significantly decrease all-cause mortality among hospitalized pediatric patients,” the researchers concluded. “These findings do not support the use of this system to reduce mortality.”

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Ozempic MDL Court To Evaluate Need for Gastroparesis Diagnostic Testing in GLP-1 Lawsuits
Ozempic MDL Court To Evaluate Need for Gastroparesis Diagnostic Testing in GLP-1 Lawsuits (Posted yesterday)

A federal judge has agreed to divide lawsuits over gastroparesis injuries linked to drugs like Ozempic and Mounjaro into multiple phases, examining how the condition is diagnosed and whether plaintiffs' claims are preempted by federal laws.

Adult Woman Files Similac Lawsuit Over NEC Injuries Experienced as a Newborn
Adult Woman Files Similac Lawsuit Over NEC Injuries Experienced as a Newborn (Posted 2 days ago)

Lawsuit alleges that Abbott Laboratories failed to provide families and the medical community with adequate warnings about the risks associated with it’s cow’s milk-based Similac formula, which a now adult woman indicates has left her with life-long NEC injuries.

Amended Lawsuit Over BioZorb Implant Side Effects Outlines Problems Caused By Tissue Marker Design Defects
Amended Lawsuit Over BioZorb Implant Side Effects Outlines Problems Caused By Tissue Marker Design Defects (Posted 3 days ago)

Six breast cancer patients have asked a federal judge for permission to amend a complaint filed in March 2024, which describes problems linked to the device and painful side effects experienced when the tissue marker migrated out of position or shattered inside their bodies.